181 related articles for article (PubMed ID: 25146150)
1. Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma.
Salas S; Jiguet-Jiglaire C; Campion L; Bartoli C; Frassineti F; Deville JL; Maues De Paula A; Forest F; Jézéquel P; Gentet JC; Bouvier C
BMC Cancer; 2014 Aug; 14():606. PubMed ID: 25146150
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C
Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377
[TBL] [Abstract][Full Text] [Related]
3. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma.
Kubota D; Mukaihara K; Yoshida A; Tsuda H; Kawai A; Kondo T
J Proteomics; 2013 Oct; 91():393-404. PubMed ID: 23911960
[TBL] [Abstract][Full Text] [Related]
4. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
He L; Yang H; Huang J
BMC Cancer; 2021 May; 21(1):581. PubMed ID: 34016089
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
6. p16 expression predicts neoadjuvant tumor necrosis in osteosarcomas: reappraisal with a larger series using whole sections.
Kosemehmetoglu K; Ardic F; Karslioglu Y; Kandemir O; Ozcan A
Hum Pathol; 2016 Apr; 50():170-5. PubMed ID: 26997452
[TBL] [Abstract][Full Text] [Related]
7. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
8. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.
Sadikovic B; Thorner P; Chilton-Macneill S; Martin JW; Cervigne NK; Squire J; Zielenska M
BMC Cancer; 2010 May; 10():202. PubMed ID: 20465837
[TBL] [Abstract][Full Text] [Related]
9. The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy.
Le Guellec S; Moyal EC; Filleron T; Delisle MB; Chevreau C; Rubie H; Castex MP; de Gauzy JS; Bonnevialle P; Gomez-Brouchet A
Hum Pathol; 2013 Oct; 44(10):2149-58. PubMed ID: 23845472
[TBL] [Abstract][Full Text] [Related]
10. Expression profiles of osteosarcoma that can predict response to chemotherapy.
Man TK; Chintagumpala M; Visvanathan J; Shen J; Perlaky L; Hicks J; Johnson M; Davino N; Murray J; Helman L; Meyer W; Triche T; Wong KK; Lau CC
Cancer Res; 2005 Sep; 65(18):8142-50. PubMed ID: 16166288
[TBL] [Abstract][Full Text] [Related]
11. [Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients].
Nathrath M; Kremer M; Letzel H; Remberger K; Höfler H; Ulle T
Klin Padiatr; 2002; 214(4):230-5. PubMed ID: 12165907
[TBL] [Abstract][Full Text] [Related]
12. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
[TBL] [Abstract][Full Text] [Related]
13. [P-glycoprotein expression in osteosarcoma].
Pösl M; Grahl K; Amling M; Werner M; Ritzel H; Stenzel I; Hentz M; Winkler K; Delling G
Pathologe; 1996 Jan; 17(1):50-5. PubMed ID: 8685096
[TBL] [Abstract][Full Text] [Related]
14. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma.
Iwata S; Tatsumi Y; Yonemoto T; Araki A; Itami M; Kamoda H; Tsukanishi T; Hagiwara Y; Kinoshita H; Ishii T; Nagase H; Ohira M
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036394
[TBL] [Abstract][Full Text] [Related]
15. Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.
Ryu K; Choy E; Yang C; Susa M; Hornicek FJ; Mankin H; Duan Z
J Orthop Res; 2010 Jul; 28(7):971-8. PubMed ID: 20063378
[TBL] [Abstract][Full Text] [Related]
16. Curcumin Analogue L48H37 Suppresses Human Osteosarcoma U2OS and MG-63 Cells' Migration and Invasion in Culture by Inhibition of uPA via the JAK/STAT Signaling Pathway.
Lu KH; Wu HH; Lin RC; Lin YC; Lu PW; Yang SF; Yang JS
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374783
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Rossi B; Schinzari G; Maccauro G; Scaramuzzo L; Signorelli D; Rosa MA; Fabbriciani C; Carlo B
BMC Musculoskelet Disord; 2010 Feb; 11():34. PubMed ID: 20158913
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.
Zhu KP; Zhang CL; Shen GQ; Zhu ZS
Int J Clin Exp Pathol; 2015; 8(8):8754-73. PubMed ID: 26464619
[TBL] [Abstract][Full Text] [Related]
19. Stat3 upregulates leucine-rich repeat-containing g protein-coupled receptor 4 expression in osteosarcoma cells.
Liu J; Wei W; Guo CA; Han N; Pan JF; Fei T; Yan ZQ
Biomed Res Int; 2013; 2013():310691. PubMed ID: 24455684
[TBL] [Abstract][Full Text] [Related]
20. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.
Fossey SL; Bear MD; Lin J; Li C; Schwartz EB; Li PK; Fuchs JR; Fenger J; Kisseberth WC; London CA
BMC Cancer; 2011 Mar; 11():112. PubMed ID: 21443800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
